Oric Pharmaceuticals Stock Analysis
ORIC Stock | USD 11.01 0.13 1.17% |
Oric Pharmaceuticals is undervalued with Real Value of 14.06 and Target Price of 18.64. The main objective of Oric Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Oric Pharmaceuticals is worth, separate from its market price. There are two main types of Oric Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Oric Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Oric Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. Oric Stock Analysis Notes
About 92.0% of the company shares are owned by institutional investors. The book value of Oric Pharmaceuticals was now reported as 3.09. The company recorded a loss per share of 1.88. Oric Pharmaceuticals had not issued any dividends in recent years. ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. The company was incorporated in 2014 and is headquartered in South San Francisco, California. Oric Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 83 people. To find out more about Oric Pharmaceuticals contact MD MBA at 650 388 5600 or learn more at https://www.oricpharma.com.Oric Pharmaceuticals Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Oric Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Oric Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Oric Pharmaceuticals is way too risky over 90 days horizon | |
Oric Pharmaceuticals appears to be risky and price may revert if volatility continues | |
Net Loss for the year was (127.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Oric Pharmaceuticals currently holds about 227.06 M in cash with (112.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74. | |
Oric Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
Over 92.0% of the company shares are owned by institutional investors | |
Latest headline from news.google.com: What drives ORIC Pharmaceuticals Inc. stock price - Free Stock Movement Tracking - Jammu Links News |
Oric Pharmaceuticals Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Oric Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
21st of March 2024 Upcoming Quarterly Report | View | |
13th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
21st of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Oric Largest EPS Surprises
Earnings surprises can significantly impact Oric Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-05-06 | 2024-03-31 | -0.44 | -0.37 | 0.07 | 15 | ||
2023-08-10 | 2023-06-30 | -0.57 | -0.5 | 0.07 | 12 | ||
2022-11-07 | 2022-09-30 | -0.55 | -0.63 | -0.08 | 14 |
Oric Pharmaceuticals Environmental, Social, and Governance (ESG) Scores
Oric Pharmaceuticals' ESG score is a quantitative measure that evaluates Oric Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Oric Pharmaceuticals' operations that may have significant financial implications and affect Oric Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.
Oric Stock Institutional Investors
Shares | State Street Corp | 2025-03-31 | 2.2 M | Nea Management Company, Llc | 2025-03-31 | 2.2 M | Vivo Capital, Llc | 2025-03-31 | 2.1 M | Silverarc Capital Management, Llc | 2025-03-31 | 2.1 M | First Turn Management Llc | 2025-03-31 | 2 M | Balyasny Asset Management Llc | 2025-03-31 | 2 M | Commodore Capital Lp | 2025-03-31 | 2 M | Boxer Capital Management, Llc | 2025-03-31 | 1.7 M | Mpm Oncology Impact Management Lp | 2025-03-31 | 1.4 M | Viking Global Investors Lp | 2025-03-31 | 6.6 M | Blackrock Inc | 2025-03-31 | 5.4 M |
Oric Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 938.25 M.Oric Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.47) | (0.49) | |
Return On Capital Employed | (0.57) | (0.60) | |
Return On Assets | (0.47) | (0.49) | |
Return On Equity | (0.53) | (0.55) |
Management Efficiency
Oric Pharmaceuticals has return on total asset (ROA) of (0.3087) % which means that it has lost $0.3087 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4845) %, meaning that it created substantial loss on money invested by shareholders. Oric Pharmaceuticals' management efficiency ratios could be used to measure how well Oric Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of July 19, 2025, Return On Tangible Assets is expected to decline to -0.49. In addition to that, Return On Capital Employed is expected to decline to -0.6. At present, Oric Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.01, whereas Total Assets are forecasted to decline to about 212 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 3.49 | 3.43 | |
Tangible Book Value Per Share | 3.49 | 3.45 | |
Enterprise Value Over EBITDA | (4.00) | (4.20) | |
Price Book Value Ratio | 2.31 | 2.20 | |
Enterprise Value Multiple | (4.00) | (4.20) | |
Price Fair Value | 2.31 | 2.20 | |
Enterprise Value | 506.5 M | 577.8 M |
The operational strategies employed by Oric Pharmaceuticals management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Technical Drivers
As of the 19th of July, Oric Pharmaceuticals holds the Semi Deviation of 3.52, coefficient of variation of 458.1, and Risk Adjusted Performance of 0.2124. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oric Pharmaceuticals, as well as the relationship between them.Oric Pharmaceuticals Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Simple Moving Average indicator is calculated by adding the closing price of Oric Pharmaceuticals for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Oric Pharmaceuticals short-term fluctuations and highlight longer-term trends or cycles.
Oric Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oric Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oric Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Oric Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Oric Pharmaceuticals Outstanding Bonds
Oric Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Oric Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Oric bonds can be classified according to their maturity, which is the date when Oric Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
MGM Resorts International Corp BondUS552953CD18 | View | |
Valero Energy Partners Corp BondUS91914JAA07 | View | |
US68622TAB70 Corp BondUS68622TAB70 | View | |
US68622TAA97 Corp BondUS68622TAA97 | View |
Oric Pharmaceuticals Predictive Daily Indicators
Oric Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Oric Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 22318.25 | |||
Daily Balance Of Power | (0.25) | |||
Rate Of Daily Change | 0.99 | |||
Day Median Price | 11.15 | |||
Day Typical Price | 11.1 | |||
Price Action Indicator | (0.20) | |||
Period Momentum Indicator | (0.13) | |||
Relative Strength Index | 71.66 |
Oric Pharmaceuticals Corporate Filings
17th of July 2025 Other Reports | ViewVerify | |
F4 | 2nd of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
24th of June 2025 Other Reports | ViewVerify | |
F4 | 23rd of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
11th of June 2025 Other Reports | ViewVerify | |
F4 | 9th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
6th of June 2025 Other Reports | ViewVerify |
Oric Pharmaceuticals Forecast Models
Oric Pharmaceuticals' time-series forecasting models are one of many Oric Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Oric Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Oric Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Oric Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Oric shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Oric Pharmaceuticals. By using and applying Oric Stock analysis, traders can create a robust methodology for identifying Oric entry and exit points for their positions.
Last Reported | Projected for Next Year |
Current Oric Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Oric analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Oric analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
18.64 | Strong Buy | 12 | Odds |
Most Oric analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Oric stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Oric Pharmaceuticals, talking to its executives and customers, or listening to Oric conference calls.
Oric Stock Analysis Indicators
Oric Pharmaceuticals stock analysis indicators help investors evaluate how Oric Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Oric Pharmaceuticals shares will generate the highest return on investment. By understating and applying Oric Pharmaceuticals stock analysis, traders can identify Oric Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 23.9 M | |
Common Stock Shares Outstanding | 69.7 M | |
Total Stockholder Equity | 243.1 M | |
Total Cashflows From Investing Activities | 22.1 M | |
Property Plant And Equipment Net | 2.9 M | |
Cash And Short Term Investments | 256 M | |
Cash | 59.4 M | |
Accounts Payable | 1.5 M | |
Net Debt | -56.2 M | |
50 Day M A | 8.1471 | |
Total Current Liabilities | 24.8 M | |
Non Current Assets Total | 11.9 M | |
Non Currrent Assets Other | 9 M | |
Stock Based Compensation | 20.2 M |
Complementary Tools for Oric Stock analysis
When running Oric Pharmaceuticals' price analysis, check to measure Oric Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oric Pharmaceuticals is operating at the current time. Most of Oric Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oric Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oric Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oric Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |